Advanced search
Publication Cover
Future Oncology Volume 12, 2016 - Issue 5
Submit an article Journal homepage
139
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer: What have we Learned from Prospective Trials and What Does the Future Hold?

Shankar Siva1 Division of Radiation Oncology & Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne3002, Australia;2 Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville8006, Australia
,
Christopher P Daniels1 Division of Radiation Oncology & Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne3002, AustraliaCorrespondence[email protected]
,
Rodney J Ellis3 Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH44106, USA
,
Lee Ponsky4 Department of Urology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH44106, USA
&
Simon S Lo3 Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH44106, USA
Pages 601-606 | Received 04 Jan 2016, Accepted 07 Jan 2016, Published online: 03 Feb 2016

References

  • Ning S , TrislerK, WesselsBW, KnoxSJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer80(12), 2519–2528 (1997).
  • Walsh L , StanfieldJ, ChoLet al. Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur. Urol.50(4), 795–800 (2006).
  • De Meerleer G , KhooV, EscudierBet al. Radiotherapy for renal-cell carcinoma. Lancet Oncol.15(4), e170–e177 (2014).
  • Siva S , PhamD, GillS, CorcoranNM, ForoudiF. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int.110(11 Pt B), E737–E743 (2012).
  • Kunkle DA , UzzoRG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer113(10), 2671–2680 (2008).
  • Pham D , ThompsonA, KronTet al. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int. J. Radiat. Oncol. Biol. Phys.90(5), 1061–1068 (2014).
  • Ponsky L , LoSS, ZhangYet al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother. Oncol.117(1), 183–187 (2015).
  • Staehler M , BaderM, SchlenkerBet al. Single fraction radiosurgery for the treatment of renal tumors. J. Urol.193(3), 771–775 (2015).
  • Donat SM , DiazM, BishoffJTet al. Follow-up for clinically localized renal neoplasms: AUA guideline. J. Urol.190(2), 407–416 (2013).
  • Kang S , ZhangA, PandharipandeP, ChandaranaH, BraithwaiteR, LittenbergB. DWI for renal mass characterization: systematic review and meta-analysis of diagnostic test performance. Am. J. Roentgenol.205(2), 317–324 (2015).
  • Jeon TY , KimCK, KimJH, ImGH, ParkBK, LeeJH. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging. Br. J. Radiol.88, 20150163 (2015).
  • Parameswaran B , LauE, BergenNet al. Diffusion weighted imaging MR evaluation of renal lesions: preliminary results. J. Med. Imaging Radiat. Oncol.57(S1), 317–324 (2013).
  • D’alimonte L , HelouJ, ShermanCet al. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer. Brachytherapy14(3), 309–314 (2015).
  • Crook J , PerryG, RobertsonS, EscheB. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology45(4), 624–632 (1995).
  • Chan A , AncukiewiczM, CarballoN, MontgomeryW, WangC. The role of postradiotherapy neck dissection in supraglottic carcinoma. Int. J. Radiat. Oncol. Biol. Phys.50(2), 367–375 (2001).
  • Clinical trials database: NCT02141919. https://clinicaltrials.gov/ct2/show/NCT02141919.
  • Clinical trials database: NCT00458484. https://clinicaltrials.gov/ct2/show/NCT00458484.
  • Jackson P , ForoudiF, PhamDet al. Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial 99mTc-DMSA SPECT/CT. Radiather. Oncol.9, 253 (2014).
  • Siva S , JacksonP, KronTet al. PO-0716: Kidney function loss is directly dose dependent after SBRT for primary RCC as assessed by Cr-51 EDTA + DMSA SPECT/CT. Radiother. Oncol.115(Suppl. 1), S353–S354 (2015).
  • Clinical trials database: NCT02410174. https://clinicaltrials.gov/ct2/show/NCT02410174.
  • Siva S , PhamD, GillSet al. An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy. Radiather. Oncol.8, 248 (2013).
  • Clinical trials database: NCT02138578. https://clinicaltrials.gov/ct2/show/NCT02138578.
  • Truman JP , Garcia-BarrosM, KaagMet al. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS ONE5(8), e12310 (2010).
  • Inoue T , KinoshitaH, KomaiYet al. Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J. Surg. Oncol.10, 167 (2012).
  • Clinical trials database: NCT01099423. https://clinicaltrials.gov/ct2/show/NCT01099423.
  • Clinical trials database: NCT00930033. https://clinicaltrials.gov/ct2/show/NCT00930033.
  • Klapper JA , DowneySG, SmithFOet al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer113(2), 293–301 (2008).
  • McDermott DF , DrakeCG, SznolMet al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol.33(18), 2013–2020 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.